Slideshows Images Quizzes

Furadantin

Last reviewed on RxList: 7/26/2016
Furadantin Side Effects Center

Last reviewed on RxList 02/08/2017

Furadantin (nitrofurantoin oral suspension) is an antibiotic used to treat urinary tract infections. Furadantin is available in generic form. Common side effects of Furadantin include:

Tell your doctor if you have rare but very serious side effects effects of Furadantin including:

  • eye pain,
  • vision changes,
  • mental/mood changes,
  • persistent or severe headaches,
  • new signs of infection (e.g., fever, persistent sore throat), or
  • easy bruising or bleeding.

The usual adult dose of Furadantin is 50-100 mg four times a day. The lower dosage level is recommended for uncomplicated urinary tract infections. The usual pediatric dose is 5-7 mg/kg of body weight per 24 hours, given in four divided doses (not recommended for children under one month of age). Furadantin may interact with magnesium salicylate, choline magnesium salicylate, probenecid, or sulfinpyrazone. Tell your doctor all medications and supplements you use. During pregnancy, Furadantin should be used only when prescribed. It must not be used near the end of the pregnancy (38-42 weeks) or at the time of labor and delivery as it may cause a certain blood disorder (hemolytic anemia) in the baby. This medication passes into breast milk and may have undesirable effects on nursing infants younger than 1 month old or those with a certain genetic condition (G-6-PD deficiency). Consult your doctor before breastfeeding.

Our Furadantin (nitrofurantoin oral suspension) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Furadantin Consumer Information

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Stop using nitrofurantoin and call your doctor at once if you have a serious side effect such as:

  • diarrhea that is watery or bloody;
  • shortness of breath, running out of breath easily;
  • sudden chest pain or discomfort, wheezing, dry cough or hack;
  • fever, chills, body aches, unexplained weight loss;
  • peripheral neuropathy - numbness, tingling, or pain in your hands or feet;
  • nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);
  • pale skin, easy bruising, confusion or weakness;
  • patchy skin color, red spots, or a severe blistering, peeling, and red skin rash; or
  • severe headache, ringing in your ears, dizziness, vision problems, pain behind your eyes.

Less serious side effects may include:

  • upset stomach, vomiting;
  • mild diarrhea;
  • rust-colored or brownish urine; or
  • vaginal itching or discharge.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Furadantin (Nitrofurantoin Oral Suspension)

Furadantin Professional Information

SIDE EFFECTS

Respiratory

CHRONIC, SUBACUTE, OR ACUTE PULMONARY HYPERSENSITIVITY REACTIONS MAY OCCUR.

CHRONIC PULMONARY REACTIONS MAY OCCUR GENERALLY IN PATIENTS WHO HAVE RECEIVED CONTINUOUS TREATMENT FOR SIX MONTHS OR LONGER. MALAISE, DYSPNEA ON EXERTION, COUGH, AND ALTERED PULMONARY FUNCTION ARE COMMON MANIFESTATIONS WHICH CAN OCCUR INSIDIOUSLY. RADIOLOGIC AND HISTOLOGIC FINDINGS OF DIFFUSE INTERSTITIAL PNEUMONITIS OR FIBROSIS, OR BOTH, ARE ALSO COMMON MANIFESTATIONS OF THE CHRONIC PULMONARY REACTION. FEVER IS RARELY PROMINENT.

THE SEVERITY OF CHRONIC PULMONARY REACTIONS AND THEIR DEGREES OF RESOLUTION APPEAR TO BE RELATED TO THE DURATION OF THERAPY AFTER THE FIRST CLINICAL SIGNS APPEAR. PULMONARY FUNCTION MAY BE IMPAIRED PERMANENTLY, EVEN AFTER CESSATION OF THERAPY. THE RISK IS GREATER WHEN CHRONIC PULMONARY REACTIONS ARE NOT RECOGNIZED EARLY.

In subacute pulmonary reactions, fever and eosinophilia occur less often than in the acute form. Upon cessation of therapy, recovery may require several months. If the symptoms are not recognized as being drug-related and nitrofurantoin therapy is not stopped, the symptoms may become more severe.

Acute pulmonary reactions are commonly manifested by fever, chills, cough, chest pain, dyspnea, pulmonary infiltration with consolidation of pleural effusion on x-ray, and eosinophilia. Acute reactions usually occur within the first week of treatment and are reversible with cessation of therapy. Resolution often is dramatic. (see WARNINGS)

Changes in EKG (e.g., non-specific ST/T wave changes, bundle branch block) have been reported in association with pulmonary reactions.

Cyanosis has been reported rarely.

Hepatic

Hepatic reactions, including hepatitis, cholestatic jaundice, chronic active hepatitis, and hepatic neurosis, occur rarely. (see WARNINGS)

Neurologic

Peripheral neuropathy, which may become severe or irreversible, has occurred. Fatalities have been reported. Conditions such as renal impairment (creatinine clearance under 60 mL per minute or clinically significant elevated serum creatinine), anemia, diabetes mellitus, electrolyte imbalance, vitamin B deficiency, and debilitating diseases may increase the possibility of peripheral neuropathy (see WARNINGS)

Asthenia, vertigo, nystagmus, dizziness, headache, and drowsiness have also been reported with the use of nitrofurantoin.

Benign intracranial hypertension (pseudotumor cerebri), confusion, depression, optic neuritis, and psychotic reactions have been reported rarely. Bulging fontanels, as a sign of benign intracranial hypertension in infants, have been reported rarely.

Dermatologic

Exfoliative dermatitis and erythema multiforme (including Stevens-Johnson syndrome) have been reported rarely. Transient alopecia also has been reported.

Allergic

A lupus-like syndrome associated with pulmonary reactions to nitrofurantoin has been reported. Also, angioedema; maculopapular, erythematous, or eczematous eruptions; pruritus; urticaria; anaphylaxis; arthralgia; myalgia; drug fever; and vasculitis (sometimes associated with pulmonary reactions) have been reported. Hypersensitivity reactions present the most frequent spontaneously-reported adverse events in world-wide postmarketing experience with nitrofurantoin formulations.

Gastrointestinal

Nausea, emesis, and anorexia occur most often. Abdominal pain and diarrhea are less common gastrointestinal reactions. These dose-related reactions can be minimized by reduction of dosage. Sialadenitis and pancreatitis have been reported. There have been sporadic reports of pseudomembranous colitis with the use of nitrofurantoin. The onset of pseudomembranous colitis symptoms may occur during or after antimicrobial treatment. (see WARNINGS)

Hematologic

Cyanosis secondary to methemoglobinemia has been reported rarely.

Miscellaneous

As with other antimicrobial agents, superinfections caused by resistant organisms, e.g., Pseudomonas species or Candida species, can occur. There are sporadic reports of Clostridium difficile superinfections, or pseudomembranous colitis, with the use of nitrofurantoin.

Laboratory Adverse Events

The following laboratory adverse events have been reported with the use of nitrofurantoin; increased AST (SGOT), increased ALT (SGPT), decreased hemoglobin, increased serum phosphorus, eosinophilia, glucose-6-phosphate dehydrogenase deficiency anemia (see WARNINGS), agranulocytosis, leukopenia, granulocytopenia, hemolytic anemia, thrombocytopenia, megaloblastic anemia. In most cases, these hematologic abnormalities resolved following cessation of therapy. Aplastic anemia has been reported rarely.

Read the entire FDA prescribing information for Furadantin (Nitrofurantoin Oral Suspension)

Related Resources for Furadantin

Related Health

Read the Furadantin User Reviews »

© Furadantin Patient Information is supplied by Cerner Multum, Inc. and Furadantin Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors